TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05423691: Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Sponsor: Cellenkos, Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$633,420

Rescue Site Savings

+$422,280

Unlock Full NCT05423691 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05423691 Rescue Dossier →